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1. Introduction 
Cyclic GMP-dependent protein kinase (PKG) was discovered in 1970 in lobster muscle (Kuo 
& Greengard, 1970). It is a serine/threonine protein kinase specifically activated by cyclic 
guanosine monophosphate (cGMP). PKG is a ubiquitous intracellular second messenger 
mediating the biological effects of cGMP elevating agents including nitric oxide (NO), 
natriuretic peptides, and guanylin (an intestinal peptide involved in intestinal fluid 
regulation). It is now well recognized that PKG plays a central role in a broad range of 
physiological processes, such as contractility and proliferation of smooth muscle and cardiac 
myocytes, platelet aggregation, synaptic plasticity and learning, behavior, intestinal chloride 
reabsorption, renin secretion, and endochondral ossification (Francis et al., 2010; Hofmann 
et al., 2009; Lincoln et al., 2001; Lohmann & Walter, 2005). This chapter will focus on the role 
of PKG in the regulation of cardiovascular functions under physiological and 
pathophysiological conditions.  
2. PKG structure and tissue distribution  
In mammalian cells PKG exists as two types, PKG-I and PKG-II, respectively. They are 
encoded by two separated genes prkg1 and prkg2. The human prkg1 gene is located on 
chromosome 10 at p11.2 - q11.2 and has 15 exons. The NH2 terminus (the first 100 residues) 
of PKG I is encoded by two alternative exons that produce the isoforms PKG Iǂ and PKG Iǃ. 
The human prkg2 gene is located on chromosome 4 at q13.1 - q21.1 and has 19 exons. PKG-I 
and PKG-II is composed of two identical subunits of the homodimer about 75-80 kDa and 
84-86 kDa, respectively and shares common structural features. Each subunit of the enzyme 
consists of a regulatory domain and a catalytic domain. The regulatory domain is composed 
of an N-terminal domain and a cGMP binding domain. The N-terminal domain mediates 
homodimerization, suppression of the kinase activity in the absence of cGMP, and 
interactions with other proteins including protein substrates. The cGMP binding domain 
contains a high and a low cGMP affinity binding sites. The two cGMP-binding sites interact 
allosterically. Binding of cGMP releases the inhibition of the catalytic center by the N-
terminal autoinhibitory/pseudosubstrate domain and allows the phosphorylation of target 
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proteins. The catalytic domain contains a MgATP and a target protein-binding site, which 
catalyze the phosphate transfer from ATP to the hydroxyl group of a serine/threonine side 
chain of the target protein. When stimulated with cGMP, the phosphotransferase activity 
increases by 3- to 10-fold (Francis et al., 2010; Hofmann et al., 2009).  
PKG-I is predominantly localized in the cytoplasm (except in the platelets where it is with 
the membrane). PKG-II is anchored to the plasma membrane by N-terminal myristoylation. 
In general, PKG-I and PKG-II are expressed in different cell types. PKG-I exists at high 
concentrations in all types of smooth muscle cells (~0.1µM) including vascular smooth 
muscle cells and at lower levels in vascular endothelium and cardiomyocytes. The enzyme 
has also been detected in other cell types such as fibroblasts, certain types of renal cells and 
leukocytes, and in specific regions of the nervous system. Platelets express predominantly 
PKG Iǃ while both PKG Iǂ and PKG Iǃ isoforms are present in smooth muscle, including 
uterus, blood vessels, intestines, and trachea. PKG-II is expressed in several brain nuclei, 
intestinal mucosa, kidney, chondrocytes and the lung but not in cardiac and vascular 
myocytes (Francis et al., 2010; Hofmann et al., 2009). 
Existing research results show that PKG-I is the major type of the enzymes in the 
cardiovascular system involved in the regulation of vascular tone, regulation of vascular 
smooth muscle cells and myocardial cells proliferation and phenotypic modulation, and 
inhibiting platelet aggregation. Both PKG-Iǂ and PKG-Iǃ can be specially activated by 
cGMP, with the former is about 10 times more sensitive to cGMP than the latter. PKG can 
also be activated by cAMP, although more than 100 times less potent than cGMP. The main 
role of PKG-II is phosphorylation in the intestinal mucosa of cystic fibrosis transmembrane 
conductance regulator, regulation of intestinal chloride ion/fluid secretion, inhibition of 
renin secretion in the kidney, and the regulation of bone tissue and bone endochondral bone 
growth (Francis et al., 2010; Hofmann et al., 2009; Lincoln et al., 2001; Lohmann & Walter, 
2005). 
3. PKG function in the cardiovascular system  
3.1 Blood vessels 
3.1.1 Vasodilatation 
PKG is involved in vasodilatation caused by cGMP elevating agents including endothelium-
derived NO, ANP, CNP, and exogenous nitrovasodilators (Gao, 2010; Hofmann et al., 2009). 
In certain vessel types such as ovine perinatal pulmonary artery and vein (Dhanakoti et al., 
2000; Gao et al., 1999) as well as porcine coronary artery and vein (Qin et al., 2007; Qi et al., 
2007) relaxation caused by nitrovasodilators is primarily mediated by PKG. Studies show 
that the expression and activity of PKG can be modulated by physiological variables such as 
oxygenation (Gao et al., 2003).  
Activation of calcium activated potassium (BK) channels has been implicated as a 
mechanism for PKG-mediated relaxation of vascular smooth muscle in a number of vessel 
types including cerebral artery (Robertson et al., 1993), coronary artery (White et al., 2000), 
and pulmonary artery (Barman et al., 2003), which leads to increased membrane polarization 
and thus decreased Ca2+ influx and vasodilatation. PKG may stimulate BK channels by 
direct phosphorylation of the ǂ-subunit at serine 1072 (Fukao et al., 1999) or through 
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activation of protein phosphatase 2A (Zhou et al., 1996). In ovine basilar arterial smooth 
muscle cells PKG has been shown to play a larger role in the regulation of BK activity in 
fetal than in adult myocytes, indicating a developmental changes in the role of PKG (Lin et 
al., 2005). 
PKG may also modulate Ca2+ release from the inositol-trisphosphate receptor (IP3R) of the 
sarcoplasmic/endoplasmic reticulum (SERCA) through phosphorylation of IP3R-associated 
cGMP kinase substrate (IRAG), a 125-kDa protein that resides in the SERCA membrane 
in a trimeric complex with PKG Iǃ and IP3R. In aortic smooth muscle cells of mice 
expressing a mutated IRAG protein that does not interact with the IP3R the inhibition of 
cGMP on hormone-induced increases in [Ca2+]i and contractility are blunted (Geiselhöringer 
et al., 2004). NO-, ANP-, and cGMP-dependent relaxation of aortic vessels is also attenuated 
in IRAG-knockout mice (Desch et al., 2010). 
Increasing evidence has pointed to Ca2+ desensitization through interference with RhoA and 
Rho kinase (ROK) signaling as a key mechanism for PKG-mediated vasodilatation (A.P. 
Somlyo & A.V. Somlyo, 2003). PKG may phosphorylate RhoA at Ser188, resulting in 
increased extraction of Rho A from cell membranes and thus reduced activation of this small 
GTPase protein and attenuated vasocontractility (Loirand et al., 2006). PKG may suppress 
the inhibitory effect of ROK on myosin light chain phosphatase (MLCP) by phosphorylation 
of the regulatory subunit of MLCP, myosin phosphatase targeting subunit (MYPT1), at 
Ser695 and Ser852, which leads to decreased phosphorylation of MYPT1 at Thr696 and 
Thr853 by ROK, increased activity of MLCP, decreased phosphorylation of myosin light 
chain (MLC), and diminished vasoreactivity (Wooldridge et al., 2004; Gao et al., 2007 
&2008). The effect of PKG on MLCP requires its binding to the leucine zipper domain in the 
C-terminal of MYPT1. The expression of the leucine zipper domain in MYPT1 is modulated 
by various physiological and pathophyiological conditions (Chen et al., 2006; Dou et al., 
2010; Payne et al., 2006), which may alter the action of PKG on MLCP. Studies also show 
that PKG/MYPT1 signaling plays a greater role in mediating relaxation of proximal arteries 
induced by NO than that of distal arteries in coronary vasculature (Ying et al., 2011). 
A number of PKG substrates not mentioned above may also be targeted by PKG and 
involved in PKG-mediated vasodilatation, such as phosphodiesterase 5 (PDE5), 
phospholamban, and RGS (regulator of G-protein signaling) proteins (Schlossmann & 
Desch, 2009). It is worth noting that cGMP may affect vasodilatation by PKG-dependent and 
independent mechanism. Global PKG-knockout causes only a slight hypertension in young 
mice whereas in the adult the basal blood pressure of the PKG-knockout mice is not 
different from the control (Pfeifer et al. 1998), indicating other mechanisms may take place 
to compensate the lose of PKG in maintaining a normal blood pressure. 
3.1.2 Phenotype modulation and antiproliferation action  
Vascular smooth muscle cells (VSMCs) exist in either a differentiated, contractile or a 
dedifferentiated, synthetic phenotype. A normal PKG activity appears critical to maintain 
vascular smooth muscle cells in a contractile and differentiated state. Repetitively passaged 
VSMCs of the rat aorta do not express PKG and exist in the synthetic phenotype. Transfection 
of PKG Iǂ cDNA induces a morphologic change of VSMCs consistent with the contractile 
phenotype, which is prevented by the inhibition of PKG (Dey et al., 2005).  
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Myocardin is a smooth muscle and cardiac muscle-specific transcriptional coactivator of 
serum response factor (SRF) while E26-like protein-1 (Elk-1) is a SRF/myocardin transcription 
antagonist. PKG-I has been shown to decrease Elk-1 activity by sumo modification of Elk-1, 
thereby increasing myocardin-SRF activity on SMC-specific gene expression and keeping 
the cells in a contractile phenotype (Choi et al., 2010). In VSMCs of ovine fetal pulmonary 
veins hypoxia-induced reduction in PKG protein expression is closely correlated with the 
repressed expression of VSMC phenotype markers, along with a reduced expression of 
myocardin and increased expression of Elk-1. It is postulated that the increased expression 
of Elk-1 resulting from the downregulation of PKG under hypoxia displaces myocardin 
from SRF and thereby leads to suppression of SMC marker genes and activation of 
expressions of genes related with the synthetic phenotype (Zhou et al., 2007 & 2009). The 
PKG-dependent modulation of phenotypes of VSMCs appears to need the cysteine-rich LIM-
only protein CRP4 to act as a scaffolding protein that promotes cooperation between SRF and 
other transcription factors and cofactors since PKG stimulation of the SM-ǂ-actin promoter is 
suppressed when CRP4 is deficient in PKG binding (Zhang et al., 2007).  
PKG has been reported to exert anti- and pro-atherogenic effects in vascular smooth muscle. 
In coronary and cerebral arterial smooth muscle cells (El-Mowafy et al., 2008; Luo et al., 
2011) the proliferation induced by vascular mitogens was inhibited by the cGMP elevating 
agent or PKG I transfection. However, 8-Br-cGMP stimulated proliferation of aortic SMCs 
from the wide-type mice but not from PKG I-deficient mice (Wolfsgruber et al., 2003). The 
contradictory effects may have in part resulted from differences in PKG activation levels 
(i.e., basal activation vs. hyperactivation). For instance, PKG at low activation levels 
prevents apoptosis whereas high-level activation causes apoptosis of aortic SMCs of the 
mice (Wong & Fiscus, 2010). 
3.2 Heart 
3.2.1 Cardiac contractility 
A critical role for PKG in the negative inotropic effect caused by NO and cGMP has been 
demonstrated in myocardial preparations from PKG I-deficient juvenile mice, from the 
cardiomyocyte-specific knockout adult mice (Wegener et al., 2002), and in rat ventricular 
myocytes with the PKG inhibitor (Layland et al., 2002). The Ca2+ current of rat ventricular 
cells is inhibited by cGMP and a catalytically active fragment of PKG (Mery et al., 1991). In 
murine cardiac myocytes overexpressing PKG I the basal and stimulated activities of L-type 
Ca2+ channels are inhibited by NO and the cGMP analog (Schroder et al. 2003). Hence, PKG 
may exert its negative inotropic effect action by reducing [Ca2+] i through inhibiting the 
activity of Ca2+ channels. Recent studies suggest that PKG I-mediated inhibition of L-type 
Ca2+ channels of cardiac myocytes may result from the phosphorylation of Cav 1.2 ǂ1c and ǃ2 
subunits (Yang et al., 2007).  
PKG may also reduce [Ca2+]i of cardiomyocytes through phosphorylation of phospholamban, 
which leads to an increased activity of the sarcoplasmic reticulum Ca2+-ATPase (SERCA) 
and thereby an increased Ca2+ uptake from the cytosol. Indeed, phospholamban of the 
rabbit cardiac myocytes is phosphorylated by cGMP in a manner sensitive to the inhibition 
of PKG. Moreover, the inhibitory effect of contractility of the cardiac myocytes caused by 
cGMP is prevented by the inhibition of PKG or SERCA (Zhang et al., 2005). C-type natriuretic 
www.intechopen.com
 
cGMP-Dependent Protein Kinase in the Regulation of Cardiovascular Functions 
 
341 
peptide and the cGMP analog have been found to cause positive inotropic and lusitropic 
responses of murine hearts, which are associated with an increased phosphorylation of 
phospholamban (Wollert et al., 2003). These observations are in vary with those obtained in 
studies by Zhang et al. discussed above. The underlying reasons for the different inotropic 
effects remain to be determined (Wollert et al., 2003).  
In intact cardiomyocytes of the rat, the negative inotropic and relaxant effects of DEA/NO, 
an NO donor, occur without significant changes in the amplitude or kinetics of the 
intracellular Ca2+ transient. The effect is diminished in the presence of the inhibitor of 
soluble guanylyl cyclase (sGC) or PKG, indicating a PKG-dependent Ca2+ desensitization of 
the myofilaments. Meanwhile, hearts treated with DEA/NO showed a significant increase 
in troponin I phosphorylation (Layland et al., 2002). The PKG may reduce the Ca2+ 
sensitivity of cardiac myofilaments through phosphorylation of cardiac troponin I (cTnI) at 
the same sites (Ser23/24) as those phosphorylated by PKA (Layland et al., 2005). Studies 
suggest that cardiac Troponin T may serve as an anchoring protein for PKG to facilitate 
preferential and rapid cTnI phosphorylation (Yuasa et al., 1999). 
3.2.2 Antihypertrophy 
An increased left ventricular mass has been recognized as an independent risk factor that 
correlates closely with cardiovascular risk and has strong prognostic implications. In the mice 
administration of sildenafil, which elevates cGMP level by inhibiting PDE5, suppresses the 
development of cardiac hypertrophy caused by chronic pressure overload and can even 
reverse pre-established cardiac enlargement. These effects are associated with an increased 
activity of PKG I (Takimoto et al. 2005). Mice with myocyte-specific PDE5 gene overexpression 
develop more severe cardiac hypertrophy and PKG activation is inhibited as compared to 
controls in response to pressure overload. Under such a cardiomyopathic state, the 
suppression of PDE5 expression/activity in myocytes enhanced PKG activity and reversed all 
previously amplified maladaptive responses (Zhang et al., 2010). In contrast to many studies 
which indicate an antihypertrophic role for PKG, Lukowski et al. have found that total PKG I-
knockout and myocyte-specific rescue of PKG expression (in the context of global gene 
silencing) did not affect isoproterenol and stress-induced development of cardiac hypertrophy 
in mice (Lukowski et al., 2010). It is suspected that the lack of differences between controls and 
PKG I-deficient mice may be in part due to that PKG I-targeted cascades have not been 
activated under the experimental conditions (Kass & Takimoto, 2010). 
RGSs are GTPase-accelerating proteins that promote GTP hydrolysis by the alpha subunit of 
heterotrimeric G proteins, thereby accelerating signal termination in response to GPCR 
stimulation (Schlossmann & Desch, 2009). Among more than 30 RGS proteins, RGS4 is 
richly expressed in murine coronary myocytes. In cultured cardiac myocytes, atrial 
natriuretic peptide stimulated PKG-dependent phosphorylation of RGS4 and association of 
RGS4 with the alpha subunit of Gq protein. Mice lacking guanylyl cyclase-A (GC-A), a 
natriuretic peptide receptor, have pressure-independent cardiac hypertrophy, reduced 
expression and phosphorylation of RGS4 in the hearts compared with wild-type mice. The 
RGS4 overexpression in GC-A-KO mice reduced cardiac hypertrophy and suppressed the 
augmented cardiac expressions of hypertrophy-related genes. These results suggest that 
GC-A activation may counteract cardiac hypertrophy via RGS4 in a PKG-dependent 
mechanism (Tokudome et al., 2008). It appears that ANP-cGMP-PKG-RGS signaling is 
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involved in ǃ-adrenergic but not angiotensin II (Ang II)–induced (Gs vs. Gaq mediated) 
cardiomyocyte hypertrophy. ANP attenuated Ang II-stimulated Ca2+ currents of 
cardiomycytes but had no effect on isoproterenol stimulation. The effect of ANP on Ang II 
stimulation was eliminated in cardiomyocytes of mice deficient in GC-A, in PKG I, or in 
RGS2. Furthermore, cardiac hypertrophy induced by Ang II but not by ǃ- adrenoreceptor 
was exacerbated in mice with cardiomyocyte-restricted GC-A deletion (Klaiber et al., 2010). 
Multiple subclasses of transient receptor potential (TRP) channels are expressed in the heart. 
These channels, especially the TRPC subclass, have been implicated being involved in the 
regulation of the cardiac hypertrophic response, most likely coordinating signaling within 
local domains or through direct interaction with Ca2+-dependent regulatory proteins. 
Overexpression of TRPC6 in mice lacking GC-A exacerbated cardiac hypertrophy while the 
blockade of TRPC channels attenuated the cardiac hypertrophy. ANP inhibited agonist-
evoked Ca2+ influx of murine cardiomyocytes. The inhibitory effects of ANP were abolished 
by PKG inhibitors or by substituting an alanine for threonine 69 in TRPC6, suggesting that 
PKG-dependent phosphorylation of TRPC6 at threonine 69 is a critical target of 
antihypertrophic effects elicited by ANP (Kinoshita et al., 2010) 
3.2.3 Cardioprotective action against ischemia-reperfusion injury 
In isolated murine heart and cardiomyocytes elevation of cGMP by the activators of soluble 
or particulate guanylyl cyclase, by the inhibitor of PDE5, or by the cGMP analog elicits potent 
protection against myocardial ischemia-reperfusion injury and reduces cardiomyocyte 
necrosis and apoptosis. These effects are accompanied by an increased PKG activity and 
attenuated by PKG inhibitors or by selective knockdown of PKG in cardiomyocytes (Das, 2008 
et al.; Gorbe et al., 2010). It is generally recognized that ischemia/reperfusion injury arises 
primarily from the opening of the mitochondrial permeability transition pore (mPTP) in the 
first minutes of reperfusion. cGMP-PKG signaling may prevent opening of mPTP via 
activation of the mitochondrial KATP channels, direct phosphorylation of an unknown 
protein on the mitochondrial outer membrane, and upregulation of the antiapoptotic 
protein Bcl-2 (Costa et al.,2008; Deschepper, 2010). Glycogen synthase kinase 3ǃ (GSK-3ǃ) 
plays a central role in transferring cardio protective signals downstream to target(s) that act 
at or in proximity to the mPTP. Phosphorylation and inhibition of GSK-3ǃ has also been 
demonstrated being involved in PKG-mediated cardioprotective action (Das et al., 2008; 
Juhaszova et al., 2009; Xi et al., 2010). 
3.3 eNOS activity and endothelial permeability 
PKG I has been detected within a range of 0.15 to 0.5 µg/mg cellular protein in adult artery 
and vein endothelial cells (ECs) and in microvascular ECs (Diwan et al., 1994; Draijer et al., 
1995; MacMillan-Crow et al., 1994). There are only limited studies on the role of PKG in the 
regulation of endothelial function, which is related to eNOS activity and endothelial 
permeability (Butt et al., 2000; Draijer et al., 1995; Moldobaeva et al., 2006; Rentsendorj et al., 
2008). Studies using recombinant human eNOS suggest that the enzyme can be 
phosphorylated at Ser1177, Ser633, Thr495 and activated by PKG II in a manner independent of 
Ca2+ and calmodulin (Butt et al., 2000). Cyclic GMP analog inhibits an increase in [Ca2+]i and 
endothelial permeability caused by thrombin in cultured ECs expressing PKG I but not 
those lacking PKG expressing (Draijer et al., 1995). In human pulmonary artery endothelial 
cells infected with adenovirus encoding PKG Iǃ the cGMP analog prevents the increase in 
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endothelial permeability caused by H2O2. The barrier protection effect was not affected by 
inhibition of the expression of VASP, a PKG substrate (Moldobaeva et al., 2006; Rentsendorj 
et al., 2008). 
3.4 Anti-platelet aggregation action 
Substantial evidence supports a critical role for PKG in mediating the anti-platelet 
aggregation action caused by cGMP elevating agents such as endothelium-derived NO 
(EDNO) and exogenous nitrovasodilators (Walter & Gambaryan, 2009; Dangel et al., 2010). 
PKG Iǃ is the predominate isoform of the enzyme in platelets. The concentration of PKG Iǃ 
in human platelets is 3.65μM, which is higher than that of any other cell type examined 
(Antl et al., 2007; Eigenthaler et al., 1992). In PKG-deficient murine platelets the inhibition of 
the cGMP analog on granule secretion, aggregation and adhesion is severely affected 
(Massberg et al. 1999; Schinner et al., 2011). The effect of PKG may be in part mediated by 
IRAG. IRAG is abundantly expressed in platelets and constitutively formed in a 
macrocomplex with PKGIǃ and the InsP3R. PKGIǃ phosphorylates IRAG at Ser664 and 
Ser677 in intact platelets, resulting in attenuated release of Ca2+ from the sarcoplasmic 
reticulum evoked by IP3. Targeted deletion of the IRAG-InsP3RI interaction in IRAGΔ12/Δ12 
mutant mice causes a loss of NO/cGMP-dependent inhibition of [Ca2+]i increase and platelet 
aggregation. The preventive effect of NO on arterial thrombosis in the injured carotid artery 
was observed in wide-type platelets but not in IRAGΔ12/Δ12 mutants (Antl et al. 2007). 
Vasodilator-stimulated phosphoprotein (VASP) belongs to the Ena-VASP protein family. It is 
associated with filamentous actin formation and may play a widespread role in cell adhesion 
and motility. In VASP-deficient mice, the inhibitory effect of NO on platelet adhesion is 
impaired. Under physiologic conditions, platelet adhesion to endothelial cells was enhanced in 
VASP null mutants. Under pathophyiological conditions, the loss of VASP augments platelet 
adhesion to the postischemic intestinal microvasculature, to the atherosclerotic endothelium of 
ApoE-deficient mice, and to the subendothelial matrix of blood vessels (Massberg et al. 2004). 
In VASP-deficient mice, although cGMP-mediated inhibition of platelet aggregation is 
impaired, cGMP-dependent inhibition of agonist-induced increases in cytosolic calcium 
concentrations and granule secretion is preserved (Aszódi et al., 1999). 
Although it is a currently prevailing concept that PKG signaling inhibits platelet function, 
some studies show that activation of NO-cGMP-PKG pathway promotes platelet aggregation 
(Blackmore, 2011; Li et al., 2003; Zhang et al., 2011). In PKG knockout mice platelet responses 
to von Willebrand factor (vWF) or low doses of thrombin are impaired and bleeding time is 
prolonged. Human platelet aggregation induced by these agents is also diminished by PKG 
inhibitors but enhanced by cGMP (Li et al., 2003). A defect in platelet aggregation in response 
to low doses of collagen or thrombin also occurs in platelet-specific sGC-deficient mice (Zhang 
et al., 2011). It appears that cGMP at low concentrations promotes while at higher 
concentrations inhibits platelet aggregation (Blackmore et al., 2011; Li et al., 2003).  
4. PKG and cardiovascular diseases 
4.1 Hypertension  
Global deletion of eNOS (Huang et al., 1995), sGC (Friebe et al., 2007), or PKG I (Pfeifer et al. 
1998) results in hypertension in mice. About 80% of the mice that are deficient in PKG I died 
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at age of 8-week. Those lived to adulthood showed no significant difference in blood 
pressure from the wild type animals, indicating compensatory mechanisms are functioning 
(Pfeifer et al. 1998). Loss of PKG I abolishes NO- and cGMP-dependent relaxations of 
smooth muscle (Pfeifer et al. 1998). In mice with a selective mutation in the N-terminal 
protein interaction domain of PKG Iǂ also results in reduced vasodilator response to EDNO 
and cGMP and increased systemic blood pressure, suggesting that the hypertension results 
from a diminished response of blood vessels to cGMP (Michael et al., 2008). Vascular 
reconstitution of PKG Iǂ or PKG Iǃ in PKG I-deficient mice restores the diminished 
vasodilatation to NO and cGMP and normalizes the elevated blood pressure, (Weber et al., 
2007). In spontaneously hypertensive rats (SHR) cardiomyocytes PKG-I expression is 
decreased, making the NO/cGMP-dependent regulation on calcium transient in 
cardiomyocytes weakened, and promoting cardiac hypertrophy (Mazzetti et al., 2001). 
Abnormality in the renin-angiotensin-aldosterone system is an important etiologic event in 
the development of hypertension. Renal renin mRNA levels under stimulatory (low-salt diet 
plus ramipril) and inhibitory (high-salt diet) conditions were elevated in PKG II deficient 
mice. The deletion of PKG II abolishes the attenuation of forskolin-stimulated renin 
secretion caused by 8-Br-cGMP in cultured renal juxtaglomerular cells. Activation of PKG 
by 8-Br-cGMP decreased renin secretion from the isolated perfused rat kidney of the wild-
type mice but not that of PKG II-/- mice. These findings suggest that PKG II exerts an 
inhibitory effect on renin secretion (Wagner et al., 1998). Mice deficient in PKG II display no 
elevated blood pressure, suggesting that PKG II is not critically involved in the regulation of 
overall systemic blood pressure (Hofmann et al., 2009). 
4.2 Atherosclerosis  
In an animal model of late-stage atherosclerosis obtained by feeding 8-week-old rabbits with 
hypercholesterol diet for 50 weeks the protein levels of sGC and PKG I of the aorta were 
reduced. These changes were most prominent in the neointimal layer. Phosphorylation of 
VASP at Ser239, a specific indicator of PKG activity, was also reduced. The preferential 
down-regulation of cGMP/PKG signaling in neointima suggests a direct connection of these 
changes to neointimal proliferation and vascular dysfunction occurred in atherosclerosis 
(Melichar et al., 2004). It seems that the decreased PKG expression occurred only at late-
stage atherosclerosis, as the protein level of PKG was unaltered in Watanabe heritable 
hyperlipidemic rabbits of three month old (Warnholtz et al., 2002). Thrombospondin-1 and 
osteopontin are extracellular matrix (ECM) proteins involved in the development of 
atherosclerosis. PKG may exert its anti- atherosclerotic effect in part through these two ECM 
proteins, since their expression could be marked reduced by PKG I (Dey et al., 1998). 
Interestingly, postnatal ablation of PKG I selectively in the VSMCs of mice reduced 
atherosclerotic lesion area, which would suggest that smooth muscle PKG I promotes 
atherogenesis (Wolfsgruber et al., 2003). 
4.3 Diabetic vascular disease  
High glucose exposure has been found to reduce the protein and mRNA levels of PKG I as 
well as PKG I activity in cultured rat VSMCs. PKG I protein levels were decreased in 
femoral arteries from diabetic mice. Glucose-mediated decrease in PKG I levels was 
inhibited by the superoxide scavenger or NAD(P)H oxidase inhibitors. High glucose 
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exposure increased the protein levels and phosphorylated levels of p47phox (an NADPH 
oxidase subunit) in VSMCs, associated with increased superoxide production. The 
suppressed PKG expression and increased superoxide production were prevented by 
transfection of cells with siRNA-p47phox, suggesting that NADPH oxidase-derived 
superoxide may mediate the high glucose-induced downregulation of PKG occurred in 
diabetic blood vessels (Liu et al., 2007). Studies also show that activation of PKG by 
expression of constitutively active PKG suppressed high glucose-induced VSMC 
proliferation and inhibited first gap phase (G1) to synthesis phase (S) phase progression of 
the cell cycle. These changes were accompanied with reduced glucose-induced cyclin E 
expression and cyclin E-cyclin-dependent kinase 2 activity as well as inhibition of glucose-
induced phosphorylation of retinoblastoma protein (Rb) and p27 degradation. It suggests 
that PKG may inhibit VSMC proliferation through attenuation of cyclin E expression and 
increase in p27 protein stability, which leads to decreased CDK 2 activity and reduced Rb 
phosphorylation, thereby resulting in cell cycle arrest and cell growth inhibition (Wang & 
Li, 2009). Increased activity of transforming growth factor-ǃ (TGF-ǃ) is implicated in the 
development of diabetic macrovascular fibroproliferative remodeling. High glucose was 
found to stimulate the expression of thrombospondin1 (TSP1), a major activator of 
transforming growth factor-ǃ (TGF-ǃ), and to stimulate TGF-ǃ activation in primary murine 
aortic SMCs. These effects were inhibited by overexpression of constitutively active PKG. 
Since PKG is downregulated in diabetic vasculature, it is likely that the downregulation of 
PKG action may relieve its suppression on TSP1 expression and TGF-ǃ activity, thereby 
leading to augmented vascular remodeling in diabetes (Wang et al., 2010). 
4.4 Pulmonary arterial hypertension 
PKG expression and/or activity are/is reduced in animal models of pulmonary arterial 
hypertension (PAH) induced by ligation of the ductus arteriosus of fetal lambs (Resnik et al., 
2006) and in caveolin-1 (Cav-1) knockout mice (Zhao et al., 2009). Cav-1, a 21-kDa integral 
membrane protein, is an intracellular physiological inhibitor of eNOS activity. Mice 
deficient in Cav-1 led to chronic eNOS activation and PAH. Activation of eNOS in Cav-1-/- 
lungs resulted in an impaired PKG activity through tyrosine nitration, probably at Tyr345 or 
Tyr549 of the catalytic domain of human PKG Iǂ. The PAH phenotype in Cav-1-/- lungs 
could be rescued by overexpression of PKG 1ǂ. The treatment of these mice with either a 
superoxide scavenger or an eNOS inhibitor reverses their pulmonary vascular pathology 
and PAH phenotype, suggesting that an increased peroxynitrite formed from chronic 
overproduction of NO and superoxide may result in tyrosine nitration and loss of activity of 
PKG. Clinically, lung tissues from patients with idiopathic PAH have been found to display 
reduced Cav-1 expression, increased eNOS activation, and PKG nitration (Zhao et al., 2009). 
In ovine fetal pulmonary veins hypoxic exposure also causes peroxynitrite-mediated PKG 
nitration, reduced PKG activity, and suppressed dilator response to 8-Br-cGMP (Negash et 
al., 2007). 
An upregulated ROK activity is implicated in a number of cardiovascular diseases including 
PAH (Satoh et al., 2011). ROK augments vasoconstriction primarily by inhibiting MLCP 
activity through phosphorylation of the regulatory subunit MYPT1 at Thr696 and Thr853, 
which leads to increased Ca2+-sensitization of smooth muscle. The effect of ROK can be 
counteracted by the stimulatory action of PKG through phosphorylation of MYPT1 at Ser695 
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and Ser852. Pulmonary arteries from fetuses exposed to chronic intrauterine hypoxia (CH) 
displayed thickening vessel walls and diminished relaxant response to 8-Br-cGMP, two 
important characteristics of newborn PAH (Bixby et al., 2007; Gao et al., 2007). Rp-8-Br-PET-
cGMPS, a specific PKG inhibitor, attenuated relaxation to 8-Br-cGMP in control vessels to a 
greater extent than in CH vessels while Y-27632, a ROCK inhibitor, potentiated 8-Br-cGMP-
induced relaxation of CH vessels and had only a minor effect in control vessels. The specific 
activity of PKG was decreased while ROK activity was increased in CH vessels as compared 
with the controls. The phosphorylation of MYPT1 at Thr696 and Thr853 was inhibited by 8-
Br-cGMP to a lesser extent in CH vessels than in controls. The difference was eliminated by 
Y-27632. These data indicate that the attenuated PKG-mediated relaxation in pulmonary 
arteries exposed to chronic hypoxia in utero is due to inhibition of PKG activity and due to 
enhanced ROCK activity. Increased ROCK activity may inhibit PKG action through 
increased phosphorylation of MYPT1 at Thr696 and Thr853 (Gao et al., 2007). In contrast to 
pulmonary arteries, relaxation of pulmonary veins of fetuses exposed to (CH) displayed no 
changes in the thickness of vessel walls and relaxant response to 8-Br-cGMP. In these veins 
phosphorylation of MYPT1 at Thr696 by ROK and at Ser695 by PKG was diminished as 
compared with control veins, suggesting that CH attenuates both PKG action and ROK 
action on MYPT1, resulting in an unaltered response to cGMP (Gao et al., 2008).  
Bone morphogenetic proteins (BMPs) are members of the TGF-ǃ superfamily. Mutations in 
the BMP type II receptor (BMPR-II) are responsible for the majority of cases of heritable 
PAH. Dysfunction in BMP signaling is implicated in idiopathic PAH and in a number of 
experimental models of PAH (Toshner et al., 2010). Studies found that PKG I may regulate 
the activation of BMP receptor and receptor-regulated Smad, a key mediator for BMP 
signaling, at the plasma membrane and regulate the expression of BMP target genes in the 
nucleus. These mechanisms may enable PKG I to compensate for the aberrant cellular 
responses to BMP caused by mutations in BMPRII found in PAH patients. Indeed, the 
overexpression of PKG I restores normal BMP responsiveness in cells expressing signaling 
deficient PAH mutant receptors such as the mutant BMPRII-Q657ins16 (Schwappacher et 
al., 2009; Thomson et al., 2000).  
4.5 Nitrate tolerance  
Nitroglycerine (NTG) is a widely used vasodilator in the treatment of angina pectoris and 
acute heart failure. It is converted inside the cell to NO or an NO-related intermediate and 
causes vasodilatation in a cGMP-dependent fashion. The effectiveness of NTG is often 
diminished when it is continuously used for a period of time, termed nitrate tolerance. The 
underlying mechanisms include an increased production of reactive oxygen species (ROS), 
impairment of biotransformation of NTG by aldehyde dehydrogenase, desensitization of 
sGC, upregulation of phosphodiesterases, and downregulation PKG activity (Münzel et al., 
2005). In human arteries and veins, nitrate tolerance is associated with decreased PKG 
activity (Schulz et al., 2002). In the arteries of rats and rabbits, nitrate tolerance induced by 
low-dose NTG is associated with decreased PKG activity, while the tolerance induced by 
high-dose NTG is associated with decreased PKG protein level and activity (Mülsch et al., 
2001). In porcine coronary arteries nitrate tolerance induced by NTG at low concentrations is 
prevented by the scavenger of ROS. However the tolerance induced by NTG at higher 
concentrations is not affected by the scavenger of ROS and shows cross-tolerance to the NO 
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donor and 8-Br-cGMP. Meanwhile, the protein and mRNA levels of PKG are reduced. It 
seems that the tolerance induced by NTG at higher concentrations may be due to 
suppression of PKG expression resulting from sustained activation of the enzyme (Dou et 
al., 2008). A diminished expression and activity of PKG was also observed in pulmonary 
veins of newborn lambs after prolonged exposure to the NO donor (Gao et al., 2004). 
Activation of MLCP is a key mechanism for vasodilatation induced by nitrovasodilators 
such as NTG and NO. MLCP is a heterotrimer, composed of a catalytic subunit PP1cδ, a 
regulatory subunit MYPT1, and a subunit with unknown function. The regulatory subunit 
MYPT1 exists as isoform either with or without leucine zipper domain in its C-terminal 
[MYPT1 (LZ+) and MYPT1 (LZ−), respectively]. The presence of leucine zipper is necessary 
for PKG binding to MYPT1 and for PKG-mediated stimulatory effect on MLCP. Studies 
consistently demonstrate that the expression of MYPT1 (LZ+) determines the sensitivity to 
cGMP-mediated vasodilatation (Lee et al., 2007; A.P. Somlyo & A.V. Somlyo, 2003). Nitrate 
tolerance induced under in vitro conditions in porcine coronary arteries and induced under 
in vivo preparations in murine aorta show a decreased protein levels of MYPT1 (LZ+) but 
not of PP1cδ. The decrease in the MYPT1 (LZ+) protein level of coronary artery can also be 
induced by the NO donor and 8-Br-cGMP in a manner sensitive to the inhibitors of sGC and 
PKG, respectively. The tolerance to NTG in porcine coronary artery and mouse aorta is 
ameliorated by proteasome inhibitors. Therefore a downregulation of MYPT1 (LZ+) caused 
by increased proteasome-dependent degradation may contribute to development of nitrate 
tolerance (Dou et al., 2010). 
5. Conclusion 
Overwhelming evidence, obtained by genetic manipulation and pharmacological tools, 
under both in vivo and in vitro conditions, suggests that PKG is the primary enzyme in 
mediating vasodilatation, antiproliferation of vascular smooth muscle, and anti-platelet 
aggregation action induced by endogenous and exogenous nitrovasodilators via cGMP 
elevation (Francis et al., 2010; Gao, 2010; Hofmann et al., 2009; Walter & Gambaryan, 2009). 
Studies also support a barrier protection effect in the vascular endothelium (Moldobaeva et 
al., 2006; Rentsendorj et al., 2008). Increasing evidence also suggests that PKG exerts 
negative inotropic and antihypertrophic actions in the heart (Takimoto et al. 2005; Yang et 
al., 2007; Zhang et al., 2010) as well as a cardioprotective action against ischemia-reperfusion 
injury (Das et al., 2008; Juhaszova et al., 2009; Xi et al., 2010). Despite substantial progress 
has been made in elucidating the role of PKG in the regulation of cardiovascular functions 
there are many aspects remain to be explored. For instance, the developing and ageing 
aspects for the role of PKG, the gender difference, and the heterogeneity in the role of PKG 
in different vasculatures. Also, the roles of many PKG substrates in the regulation of 
cardiovascular activities remain to be defined (Schlossmann & Desch, 2009).  
Dysfunction in NO-cGMP signaling is a common initiator and independent predictor of 
cardiovascular events (Vanhoutte et al., 2009). An impaired PKG action has been implicated 
in various cardiovascular disorders such as hypertension, atherosclerosis, diabetic vascular 
disease, pulmonary arterial hypertension, and nitrate tolerance (Francis et al., 2010; Gao, 
2010; Hofmann et al., 2009). Cardiovascular alterations are a long-term process comprising 
functional and structural changes with remarkable complexities, which undoubtedly make 
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the dissection of the role of PKG rather challenging. However, a better understanding of its 
role and the underlying mechanism will be of great therapeutic significance.  
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